Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bioventus (BVS) EBITDA (2020 - 2025)

Historic EBITDA for Bioventus (BVS) over the last 6 years, with Q3 2025 value amounting to $2.7 million.

  • Bioventus' EBITDA rose 15107.15% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.7 million, marking a year-over-year increase of 11801.75%. This contributed to the annual value of -$48.0 million for FY2024, which is 7531.33% up from last year.
  • As of Q3 2025, Bioventus' EBITDA stood at $2.7 million, which was up 15107.15% from $10.9 million recorded in Q2 2025.
  • In the past 5 years, Bioventus' EBITDA registered a high of $23.8 million during Q2 2021, and its lowest value of -$173.8 million during Q2 2023.
  • Over the past 5 years, Bioventus' median EBITDA value was -$7.0 million (recorded in 2024), while the average stood at -$22.9 million.
  • Its EBITDA has fluctuated over the past 5 years, first tumbled by 2769717.87% in 2022, then surged by 15107.15% in 2025.
  • Quarter analysis of 5 years shows Bioventus' EBITDA stood at -$319000.0 in 2021, then plummeted by 27697.18% to -$88.7 million in 2022, then surged by 91.93% to -$7.2 million in 2023, then soared by 84.19% to -$1.1 million in 2024, then surged by 337.9% to $2.7 million in 2025.
  • Its last three reported values are $2.7 million in Q3 2025, $10.9 million for Q2 2025, and -$2.7 million during Q1 2025.